Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Team in France introduces AAC-11-LZ-derived polypeptides

Sep. 10, 2015

Preclinical and phase I efficacy of a first-in-class ADC against tumor-initiating cells

Sep. 10, 2015

Five Prime starts dosing in phase I trial of FPA-008 and nivolumab

Sep. 9, 2015

Updated efficacy data reported for L-DOS-47 in NSCLC

Sep. 9, 2015

Cellectis and MD Anderson Cancer Center form collaboration for liquid tumor immunotherapy

Sep. 8, 2015

Nivolumab gets FDA orphan drug designation for the treatment of HCC

Sep. 8, 2015

FDA grants priority review to daratumumab BLA for multiple myeloma

Sep. 7, 2015

FDA accepts sBLA filing for Opdivo in previously treated non-squamous NSCLC

Sep. 4, 2015

Adaptimmune expands phase I/II trial of NY-ESO TCR therapeutic in synovial sarcoma

Sep. 4, 2015

Heat Biologics begins trial combining HS-110 and PD-1 checkpoint inhibitor in NSCLC

Sep. 3, 2015

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...